Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets trade in the green
Tue, 6 Oct 11:30 am

After opening the day on a firm note, the Indian Markets have continued to trade on a positive note. Sectoral indices are trading on a mixed note with stocks from the pharma and consumer durables sectors leading the gains. Banking and IT stocks are witnessing selling pressure.

The BSE-Sensex is trading up 89 points (up 0.3%) and the NSE-Nifty is trading up 19 points (up 0.2%). The S&P BSE Midcap index is trading up by 0.4% while the S&P BSE Smallcap index is trading up 0.8%. The rupee is trading at 65.25 to the US dollar.

Stocks in the steel space are trading in the green with gains led by Jindal Saw Ltd and Tayo Rolls. As per an article in Economic Times, Tata Steel has reported that it will review its agreement with the Alberta-based New Millennium Iron Corporation (NML) for an iron ore project in Canada. As a part of this review, Tata Steel is going to consider its current or potentially future participation in NML's recently announced alternative development approach to its taconite properties. Both the parties are intending to conclude a definitive agreement by the first quarter of 2016, subject to their respective Board approvals. Tata Steel owns about 26.2% of NML's shares through its wholly-owned subsidiary Tata Steel Global Minerals Holdings Pte Ltd. Stock of Tata Steel is presently trading up by 0.5% on the BSE.

Pharma stocks are also trading firm with Dishman Pharma and Orchid Chemicals leading the gains. As per a leading financial daily, Sun Pharmaceuticals has announced that its US subsidiary, Ranbaxy Pharmaceuticals has settled a patent litigation with Actavis over anti-acne drug Absorica. By this settlement, Ranbaxy, its partner and Actavis have entered into a non-exclusive agreement which will allow Actavis to sell the generic version of Absorica in December 2020. This will be nine months before the expiration of the patents, which is in September 2021. One must note that Ranbaxy had introduced Absorica 25 mg and 35 mg capsules in 2014 in the US. While other versions of this drug are available in US, Ranbaxy's version has additional advantages. Scrip of Sun Pharmaceuticals is trading up by 1.8%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets trade in the green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.